Total Payments
$1,084
2024 Payments
$194.73
Companies
22
Transactions
48
Medicare Patients
31,371
Medicare Billing
$9.4M
Payment Breakdown by Category
Food & Beverage$870.30 (80.3%)
Education$213.80 (19.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $870.30 | 36 | 80.3% |
| Education | $213.80 | 12 | 19.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $215.00 | 3 | $0 (2020) |
| PFIZER INC. | $194.83 | 12 | $0 (2024) |
| GENZYME CORPORATION | $70.38 | 3 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $67.76 | 3 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $64.25 | 3 | $0 (2023) |
| GlaxoSmithKline, LLC. | $50.65 | 3 | $0 (2023) |
| Ipsen Biopharmaceuticals, Inc | $48.69 | 3 | $0 (2024) |
| Celgene Corporation | $41.52 | 2 | $0 (2021) |
| Gilead Sciences, Inc. | $35.82 | 2 | $0 (2021) |
| Astellas Pharma US Inc | $35.51 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $194.73 | 9 | Ipsen Biopharmaceuticals, Inc ($48.69) |
| 2023 | $129.56 | 7 | Novartis Pharmaceuticals Corporation ($42.73) |
| 2022 | $149.90 | 7 | PFIZER INC. ($102.00) |
| 2021 | $157.14 | 8 | Celgene Corporation ($41.52) |
| 2020 | $107.00 | 6 | GlaxoSmithKline, LLC. ($30.59) |
| 2019 | $151.15 | 4 | AstraZeneca Pharmaceuticals LP ($106.84) |
| 2018 | $138.53 | 4 | AstraZeneca Pharmaceuticals LP ($94.26) |
| 2017 | $56.09 | 3 | Amgen Inc. ($22.53) |
All Payment Transactions
48 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/15/2024 | GENZYME CORPORATION | ENJAYMO (Biological) | Food and Beverage | In-kind items and services | $25.37 | General |
| Category: Hematology | ||||||
| 09/25/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $28.96 | General |
| Category: Oncology | ||||||
| 07/31/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Tazverik | Education | In-kind items and services | $16.23 | General |
| Category: Oncology | ||||||
| 05/21/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $19.38 | General |
| Category: Genetically Defined Disease | ||||||
| 04/23/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Tazverik | Education | In-kind items and services | $16.23 | General |
| Category: Oncology | ||||||
| 04/19/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $20.23 | General |
| Category: Oncology | ||||||
| 04/19/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $18.94 | General |
| Category: Oncology | ||||||
| 03/12/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $33.16 | General |
| Category: Oncology | ||||||
| 01/24/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Tazverik | Education | In-kind items and services | $16.23 | General |
| Category: Oncology | ||||||
| 11/17/2023 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $20.06 | General |
| Category: ONCOLOGY | ||||||
| 10/26/2023 | Astellas Pharma US Inc | — | Food and Beverage | In-kind items and services | $17.51 | General |
| 10/17/2023 | AbbVie Inc. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $22.00 | General |
| Category: ONCOLOGY | ||||||
| 05/11/2023 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $20.79 | General |
| Category: Oncology | ||||||
| 02/28/2023 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $21.94 | General |
| Category: Oncology | ||||||
| 01/26/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $13.92 | General |
| Category: ONCOLOGY | ||||||
| 01/26/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $13.34 | General |
| Category: ONCOLOGY | ||||||
| 11/10/2022 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $21.52 | General |
| 07/28/2022 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $12.80 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2022 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $31.80 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2022 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $12.80 | General |
| Category: ONCOLOGY | ||||||
| 05/23/2022 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $31.80 | General |
| Category: ONCOLOGY | ||||||
| 05/23/2022 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $12.80 | General |
| Category: ONCOLOGY | ||||||
| 05/10/2022 | GENZYME CORPORATION | LIBTAYO (Biological), LIBTAYO, LIBTAYO | Food and Beverage | In-kind items and services | $26.38 | General |
| Category: Oncology | ||||||
| 12/10/2021 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $24.90 | General |
| Category: Hematology | ||||||
| 11/18/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $21.92 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 101 | 7,718 | 171,225 | $7.9M | $2.3M |
| 2022 | 96 | 7,641 | 168,442 | $7.4M | $2.2M |
| 2021 | 112 | 8,560 | 196,079 | $9.0M | $2.9M |
| 2020 | 95 | 7,452 | 127,128 | $6.2M | $2.0M |
Total Patients
31,371
Total Services
662,874
Medicare Billing
$9.4M
Procedure Codes
404
All Medicare Procedures & Services
404 procedure records from CMS Medicare Utilization — Page 1 of 17
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 31 | 20,160 | $1.3M | $477,478 | 37.0% |
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 30 | 11,200 | $1.3M | $459,059 | 36.0% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 21 | 6,660 | $732,600 | $252,931 | 34.5% |
| J1930 | Injection, lanreotide, 1 mg | Office | 2023 | 16 | 3,300 | $409,200 | $146,696 | 35.8% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 69 | 113 | $461,407 | $115,576 | 25.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 531 | 1,056 | $267,168 | $89,519 | 33.5% |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2023 | 16 | 1,760 | $176,000 | $62,781 | 35.7% |
| J1449 | Injection, eflapegrastim-xnst, 0.1 mg | Office | 2023 | 15 | 1,982 | $197,472 | $58,485 | 29.6% |
| Q5118 | Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | Office | 2023 | 16 | 2,100 | $331,800 | $52,999 | 16.0% |
| J1627 | Injection, granisetron, extended-release, 0.1 mg | Office | 2023 | 81 | 11,300 | $135,600 | $51,530 | 38.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 315 | 557 | $167,100 | $50,054 | 30.0% |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 2023 | 16 | 1,530 | $283,050 | $37,534 | 13.3% |
| Q5123 | Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | Office | 2023 | 11 | 1,080 | $119,880 | $37,296 | 31.1% |
| J3490 | Unclassified drugs | Office | 2023 | 80 | 121 | $93,358 | $29,142 | 31.2% |
| Q5116 | Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg | Office | 2023 | 12 | 1,203 | $246,615 | $25,155 | 10.2% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 16 | 1,380 | $55,200 | $25,143 | 45.5% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 26 | 21,750 | $65,250 | $18,784 | 28.8% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 113 | 120 | $72,116 | $18,177 | 25.2% |
| 78816 | Nuclear medicine study whole body with ct scan | Office | 2023 | 11 | 17 | $71,060 | $17,587 | 24.7% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 511 | 1,685 | $60,660 | $17,269 | 28.5% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 76 | 125 | $56,250 | $15,418 | 27.4% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 28 | 2,400 | $67,200 | $14,634 | 21.8% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 255 | 712 | $49,128 | $14,312 | 29.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 91 | 91 | $44,590 | $14,192 | 31.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 535 | 1,812 | $47,112 | $13,672 | 29.0% |
About Dr. Charles Taylor, M.D
Dr. Charles Taylor, M.D is a Hematology & Oncology healthcare provider based in Tulsa, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1003859679.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Charles Taylor, M.D has received a total of $1,084 in payments from pharmaceutical and medical device companies, with $194.73 received in 2024. These payments were reported across 48 transactions from 22 companies. The most common payment nature is "Food and Beverage" ($870.30).
As a Medicare-enrolled provider, Taylor has provided services to 31,371 Medicare beneficiaries, totaling 662,874 services with total Medicare billing of $9.4M. Data is available for 4 years (2020–2023), covering 404 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Tulsa, OK
- Active Since 06/13/2006
- Last Updated 05/01/2015
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1003859679
Products in Payments
- LYNPARZA (Drug) $201.10
- IBRANCE (Drug) $140.49
- OPDIVO (Biological) $50.88
- Onivyde (Drug) $48.69
- PLUVICTO (Drug) $42.73
- REBLOZYL (Biological) $41.78
- PADCEV (Biological) $39.17
- Epkinly (Drug) $33.16
- TRELEGY ELLIPTA (Drug) $30.59
- LIBTAYO (Biological) $26.38
- ENJAYMO (Biological) $25.37
- ORGOVYX (Drug) $23.93
- Trodelvy (Drug) $23.90
- ADCETRIS (Biological) $23.08
- Lonsurf (Drug) $22.72
- Neulasta (Biological) $22.53
- VENCLEXTA (Drug) $22.00
- Enhertu (Drug) $21.43
- Imbruvica (Drug) $20.83
- OJJAARA (Drug) $20.06
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Tulsa
Dr. Edwin Mccreary, M.d, M.D
Hematology & Oncology — Payments: $477,532
Hematology & Oncology $477,532
Dr. Ali Moussa, M.d, M.D
Hematology & Oncology — Payments: $11,003
Hematology & Oncology $11,003
Supriya Koya, Md, MD
Hematology & Oncology — Payments: $6,558
Hematology & Oncology $6,558
Dr. Vicki Baker, M.d, M.D
Hematology & Oncology — Payments: $5,946
Hematology & Oncology $5,946
Dr. Mark Olsen, M.d, M.D
Hematology & Oncology — Payments: $4,652
Hematology & Oncology $4,652
Dr. Jennifer Trottman, Md, MD
Hematology & Oncology — Payments: $4,488
Hematology & Oncology $4,488